Tag: mogad

CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease

Posted by: The Sumaira Foundation in

Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients

Posted by: The Sumaira Foundation in

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies

Posted by: The Sumaira Foundation in

HCP South Africa

Posted by: The Sumaira Foundation in

The Human Collective Project (HCP) is TSF’s support group meeting offered to anyone who has been affected/impacted by NMOSD/MOGAD. The program came into existence during the height of the COVID-19 […]

Efficacy and Safety of Rituximab in Central Nervous System Demyelinating Disorders (Indian context)

Posted by: The Sumaira Foundation in

Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease

Posted by: The Sumaira Foundation in

Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Posted by: The Sumaira Foundation in

HCP South Africa

Posted by: The Sumaira Foundation in

The Human Collective Project (HCP) is TSF’s support group meeting offered to anyone who has been affected/impacted by NMOSD/MOGAD. The program came into existence during the height of the COVID-19 […]

MOGAD – Pytania Pacjentów – Odpowiedzi Specjalisty

Posted by: The Sumaira Foundation in

Po raz pierwszy w Polsce na pytania pacjentów dotyczące MOGAD odpowie dr hab. Maciej Juryńczyk, Ordynator Oddziału Neurologicznego w Szpitalu Wolskim w Warszawie, neurolog specjalizujący się w leczeniu tej rzadkiej […]

Event Recap | Celebrating 9 Years of TSF

Posted by: The Sumaira Foundation in News & Announcements

On Friday, September 8, 2023, we were honored to celebrate 9 years of The Sumaira Foundation alongside many of the leading neuroimmunologists and researchers who were in Boston for the […]